Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).
Esophageal Squamous Cell Carcinoma
DRUG: Anlotinib|DRUG: Placebo
Progress free survival (PFS), From randomizationï¼Œeach 42 days up to PD or death(up to 24 months)
Overall Survival (OS), From randomization until death (up to 24 months)|Objective Response Rate (ORR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Disease Control Rate (DCR), each 42 days up to intolerance the toxicity or PD (up to 24 months)
To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).